ChemoCentryx Granted EU Orphan Drug Designation

ChemoCentryx (NASDAQ:CCXI) announced the European Medicines Agency granted avacopan an orphan medical designation for the treatment of patients with C3 glomerulopathy.
As quoted in the press release:

In March, ChemoCentryx announced that the U.S. Food and Drug Administration (FDA) had granted orphan drug designation for avacopan in the treatment of C3G. Orphan drug designation can help expedite a drug candidate’s path to market and provide certain exclusive marketing advantages after approval. ChemoCentryx plans to initiate a multi-center clinical endpoint study of avacopan for the treatment of C3G in mid-2017.
C3G is a severe kidney disease characterized by deposits of proteins from the body’s complement system into and around the kidney’s filtration units, the glomeruli. The deposition of complement protein disrupts kidney function and also triggers a profoundly destructive inflammation of the kidney. The disease process ultimately leads to renal failure, with the need for dialysis and kidney transplant.

As quoted in the press release.

Source: globenewswire.com